Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor

导出原文传递

翻译打印收藏纠错

作者： McCaffery,I. ^[1] ; Tudor,Y. ^[2] ; Deng,H. ^[3] ; Tang,R. ^[4] ; Suzuki,S. ^[5] ; Badola,S. ; Kindler,H.L. ; Fuchs,C.S. ; Loh,E. ; Patterson,S.D. ; Chen,L. ; Gansert,J.L.

作者单位： Amgen Inc., Cambridge, United States ^[1] Amgen Inc., Thousand Oaks, One DNA Way, South San Francisco, CA 94080, United States ^[2] Amgen Inc., South San Francisco, CA, United States ^[3] Dana-Farber Cancer Institute, Boston, MA, United States ^[4] University of Chicago, Medical Center, Chicago, IL, United States ^[5]

发布时间 2013-12-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Clinical cancer research

2013年19卷15期

4282-4289页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除